Management of Children With β-Thalassemia Intermedia: Overview, Recent Advances, and Treatment ChallengesAdly, Amira, A., MD*; Ismail, Eman, A., MD†Journal of Pediatric Hematology/Oncology: May 2018 - Volume 40 - Issue 4 - p 253–268 doi: 10.1097/MPH.0000000000001148 Review Article Abstract Author Information Our knowledge of the various clinical morbidities that thalassemia intermedia (TI) patients endure has substantially increased over the past decade. It is mandatory to grasp a solid understanding of disease-specific complications in order to tailor management. The optimal course of management for TI patients has been hard to identify, and several controversies remain with regard to the best treatment plan. Although advances in TI are moving at a fast pace, many complications remain with no treatment guidelines. Studies that expand our understanding of the mechanisms and risk factors, as well as clinical trials evaluating the roles of available treatments, will help establish management guidelines that improve patient care. Novel therapeutic modalities are now emerging. This article focuses on the management of children with β-TI. We present various clinical morbidities and their association with the underlying disease pathophysiology and risk factors. All therapeutic options, recent advances, and treatment challenges were reviewed. *Pediatrics Department †Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt A.A.A. and E.A.I. contributed equally and drafted and revised the manuscript content. The authors declare no conflict of interest. Reprints: Amira A. Adly, MD, 6 A ElSheshini Street, Shoubra, Soudia Buildings, Cairo 11672, Egypt (e-mail: firstname.lastname@example.org). Received August 5, 2017 Accepted December 18, 2017 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.